<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856165</url>
  </required_header>
  <id_info>
    <org_study_id>P150931</org_study_id>
    <nct_id>NCT02856165</nct_id>
  </id_info>
  <brief_title>High-flow Nasal Oxygen Therapy in Hospitalized Infant With Moderate-to-severe Bronchiolitis</brief_title>
  <acronym>BRONCHOPTI</acronym>
  <official_title>High-flow Nasal Oxygen Therapy (Optiflow) in Hospitalized Infant With Moderate-to-severe Bronchiolitis: Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last decade, high-flow nasal oxygen therapy (HFN) has emerged as a new method to
      provide respiratory support in children with moderate to severe bronchiolitis.

      However, any randomized clinical trial (RCT) have demonstrated that earlier support with HFN
      is superior to standard care including low -flow nasal oxygen therapy to reduce the risk of
      acute respiratory failure requiring non invasive (or tracheal) ventilation and subsequently
      the need of PICU transfer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, non-blinded multi-centre, randomised controlled trial comparing standard care
      including oxygen delivery via HFN versus standard nasal oxygen therapy in infants admitted to
      hospital with moderate-to-severe bronchiolitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Actual">November 23, 2017</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient in treatment failure in each group (control or HFN) requiring non-invasive (or endotracheal) ventilation and ventilation-support free days</measure>
    <time_frame>Up to an average of 7 days</time_frame>
    <description>Treatment failure is defined if one or more following criteria are met: refractory apnea (&gt; 3/h), oxygen requirement in HFN therapy arm exceeds fraction of inspired oxygen (FiO2) ≥ 40 % or oxygen requirement in standard nasal oxygen therapy arm exceeds &gt;2l/min to maintain oxygen saturation (SpO2) ≥94 %), m-WCAS score increased compared to admission at H6 and/or &gt; 5 , PaCO2 (H6 ) increased compared to admission and &gt; 60-70 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfer to pediatrics intensive care unit (PICU)</measure>
    <time_frame>at the end of the follow up (an average of 7 days)</time_frame>
    <description>Numbers of infants transferred to PICU in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in paediatric general ward unit</measure>
    <time_frame>at the end of the follow up (an average of 7 days)</time_frame>
    <description>number of days between the enrolment and return to home or the transfer to PICU when appropriate (treatment failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxgen-support free days</measure>
    <time_frame>at the end of the follow up (an average of 7 days)</time_frame>
    <description>number of oxygen support free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Artificial nutritional-support free days</measure>
    <time_frame>at the end of the follow up (an average of 7 days)</time_frame>
    <description>number of artificial nutritional-support free days (enteral feeding or intravenous line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of short term respiratory status</measure>
    <time_frame>at the end of the follow up (an average of 7 days)</time_frame>
    <description>Sequential assessment of short term (H1, 6, 12, 24) respiratory status including respiratory rate, heart-rate, SpO2, m-WCAS score, transcutaneous carbon dioxide partial pressure (tcPaCO2).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>High-flow nasal canula oxygen therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&amp;Paykel (F&amp;P), NZ)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-flow oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-flow oxygen therapy with standard nasal canula</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flow nasal canula oxygen therapy</intervention_name>
    <description>High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&amp;P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 &gt; 94%.</description>
    <arm_group_label>High-flow nasal canula oxygen therapy</arm_group_label>
    <other_name>Optiflow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-flow oxygen therapy with standard nasal canula</intervention_name>
    <description>flow adjusted to SpO2 &gt; 94% (up to a maximum of 2l/min).</description>
    <arm_group_label>Low-flow oxygen therapy</arm_group_label>
    <other_name>Low-flow oxygen therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first episode of hospitalised bronchiolitis (as defined by American Academy of
             Pediatrics clinical criterions )

          -  aged 7 days- 6 months

          -  transcutaneous SpO2 in room air &lt; 95%

          -  modified Wood's Clinical Asthma Score (m-WCAS) ≥ 2 et ≤ 5

          -  agreement of at least one of the parents or legal tutor for his child to participate
             in biomedical research

          -  affiliation to social security (beneficiary or entitled), except beneficiary of State
             medical help

        Exclusion Criteria:

          -  Urgent need for mechanical ventilation support either by nCPAP ou endotracheal route

          -  Severe form defined by modified Wood's Clinical Asthma Score (mWCAS) exceeding 5 or 6,
             requiring non invasive ventilation (n CPAP)

          -  Uncorrected cyanotic heart disease, innate immune deficiency, cranio-facial
             malformation, congenital stridor, tracheotomy

          -  Inclusion in other observational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe DURAND, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Bicêtre Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP, Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infant</keyword>
  <keyword>oxygen therapy</keyword>
  <keyword>High flow nasal canula oxygen therapy</keyword>
  <keyword>Bronchiolitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

